Synonyms: compound 12 [PMID: 30869888]
Compound class:
Synthetic organic
Comment: AZD5718 is an inhibitor of 5-LOX activating protein (FLAP) that was developed by Astra Zeneca [4]. It is orally active and is suitable for once-daily dosing. Initial clinical findings from a first-in-human study confirmed AZD5718 target engagement, and indicated that the compound is safe and well tolerated [2]. It is being advanced for further evaluation in patients with coronary artery disease. The 5-LOX pathway has been targeted for drug development as an intervention in a number of diseases where chronic inflammation drives the pathophysiology (e.g. asthma, chronic obstructive pulmonary disease and atherosclerotic coronary artery disease). Since FLAP is a crucial regulator of 5-LOX activity, it too is being pursued as a druggable anti-inflammatory target. FLAP inhibitors and 5-LOX inhibitors reduce production of the leukotriene precursor LTA4 [1,3].
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-3-yl)cyclohexane-1-carboxamide |
Synonyms |
compound 12 [PMID: 30869888] |
Database Links | |
GtoPdb PubChem SID | 384403633 |
PubChem CID | 122678117 |
Search Google for chemical match using the InChIKey | ROTWSDMXHVGAHZ-QZTJIDSGSA-N |
Search Google for chemicals with the same backbone | ROTWSDMXHVGAHZ |
UniChem Compound Search for chemical match using the InChIKey | ROTWSDMXHVGAHZ-QZTJIDSGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ROTWSDMXHVGAHZ-QZTJIDSGSA-N |